Literature DB >> 34997307

Prediction of molecular interactions and physicochemical properties relevant for vasopressin V2 receptor antagonism.

Ania de la Nuez Veulens1, Yoanna M Álvarez Ginarte2, Rolando E Rodríguez Fernandez3, Fabrice Leclerc4, Luis A Montero Cabrera2.   

Abstract

We have developed two ligand- and receptor-based computational approaches to study the physicochemical properties relevant to the biological activity of vasopressin V2 receptor (V2R) antagonist and eventually to predict the expected binding mode to V2R. The obtained quantitative structure activity relationship (QSAR) model showed a correlation of the antagonist activity with the hydration energy (EH2O), the polarizability (P), and the calculated partial charge on atom N7 (q6) of the common substructure. The first two descriptors showed a positive contribution to antagonist activity, while the third one had a negative contribution. V2R was modeled and further relaxed on a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocoline (POPC) membrane by molecular dynamics simulations. The receptor antagonist complexes were guessed by molecular docking, and the stability of the most relevant structures was also evaluated by molecular dynamics simulations. As a result, amino acid residues Q96, W99, F105, K116, F178, A194, F307, and M311 were identified with the probably most relevant antagonist-receptor interactions on the studied complexes. The proposed QSAR model could explain the molecular properties relevant to the antagonist activity. The contributions to the antagonist-receptor interaction appeared also in agreement with the binding mode of the complexes obtained by molecular docking and molecular dynamics. These models will be used in further studies to look for new V2R potential antagonist molecules.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  AVP; Docking; GPCR; Molecular dynamics simulations; QSAR; V2R; Vasopressin antagonist

Mesh:

Substances:

Year:  2022        PMID: 34997307     DOI: 10.1007/s00894-021-05022-6

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  53 in total

Review 1.  Molecular pharmacology and modeling of vasopressin receptors.

Authors:  M Thibonnier; P Coles; A Thibonnier; M Shoham
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

Review 2.  Rationale for early treatment of polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  Pediatr Nephrol       Date:  2014-07-15       Impact factor: 3.714

3.  Polycystic kidney disease: Tolvaptan in ADPKD-TEMPO 3:4 trial results.

Authors:  Rebecca Kelsey
Journal:  Nat Rev Nephrol       Date:  2012-11-27       Impact factor: 28.314

Review 4.  Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis.

Authors:  Antonio Facciorusso; Annabianca Amoruso; Viviana Neve; Matteo Antonino; Valentina Del Prete; Michele Barone
Journal:  World J Hepatol       Date:  2014-11-27

Review 5.  Vasopressin: physiology, assessment and osmosensation.

Authors:  L Bankir; D G Bichet; N G Morgenthaler
Journal:  J Intern Med       Date:  2017-07-26       Impact factor: 8.989

6.  Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Authors:  Wendy E Boertien; Esther Meijer; Paul E de Jong; Gert J ter Horst; Remco J Renken; Eric J van der Jagt; Peter Kappert; John Ouyang; Gerwin E Engels; Willem van Oeveren; Joachim Struck; Frank S Czerwiec; Dorothee Oberdhan; Holly B Krasa; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2015-01-15       Impact factor: 8.860

7.  Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.

Authors:  Miki Aihara; Hiroyuki Fujiki; Hiroshi Mizuguchi; Katsuji Hattori; Koji Ohmoto; Makoto Ishikawa; Keisuke Nagano; Yoshitaka Yamamura
Journal:  J Pharmacol Exp Ther       Date:  2014-02-25       Impact factor: 4.030

8.  Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype.

Authors:  Tamio Yamaguchi; Darren P Wallace; Brenda S Magenheimer; Scott J Hempson; Jared J Grantham; James P Calvet
Journal:  J Biol Chem       Date:  2004-07-19       Impact factor: 5.157

9.  Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Xiaofang Wang; Qi Qian; Stefan Somlo; Peter C Harris; Vincent H Gattone
Journal:  Nat Med       Date:  2004-02-29       Impact factor: 53.440

Review 10.  Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

Authors:  Maurice Manning; Stoytcho Stoev; Bice Chini; Thierry Durroux; Bernard Mouillac; Gilles Guillon
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.